Las Vegas – CRWENewswire.com would like to highlight a stock watch on Power3 Medical Products, Inc. (OTC BB:PWRM.OB) which announced today May 28, 2009 a significant breakthrough related to the diagnosis of patients with Alzheimer's. This breakthrough, which involved the successful diagnoses of different forms of Alzheimer's, including high-risk patients, was achieved during the initial phase of clinical validation trials of the Company's NuroPro® AD blood test. Prospective clinical validation trials of the NuroPro® AD for newly drawn samples, phase one for which is now complete, confirmed previous results recorded by Power3.
The NuroPro AD test was developed to help clinicians diagnose patients with Alzheimer's, as well as to distinguish those with Alzheimer's from normal individuals and patients with other neurological disorders. The NuroPro test, developed by Power3, utilizes a panel of blood serum protein biomarkers to determine the probability that a patient has Alzheimer's. The tests are intended to solve a critical challenge facing physicians, clinicians, and patients toward an objective, early stage and accurate diagnosis of actual disease.
"In the US, there are an estimated 5.1 million individuals with Alzheimer's disease," said Power3's President and Chief Scientific Officer, Dr. Ira L. Goldknopf. "The annual treatment per patient is currently in excess of $30 thousand for Alzheimer's."
Power3 is conducting the independent validation of both their Alzheimer's (NuroPro AD) and Parkinson's (NuroPro PD) tests with key clinical centers. The second phase of these prospective trials, as well as the launch of the CLIA-certified testing services, are both slated to commence sometime in late 2009.
According to Helen R. Park, CEO of Power3, "Progress thus far of the Company's clinical validation trials confirms our belief that Power3's NuroPro AD will significantly help physicians make diagnoses and recommend appropriate follow-up and treatment options for their patients, based on the presence of disease. This is a huge advance over only being capable of informing a patient that his or her risk is high."
About CRWENewswire.com
CRWENewswire.com is an independent electronic informative online financial news publication company dedicated in providing company associates, business and financial professionals with economic and investment information, as well as stock highlights. CRWENewswire and DrStockPick.com are Crown Equity Holdings, Inc. division companies.
CRWENewswire.com is not a registered investment advisor or broker-dealer. CRWENewswire.com, and Crown Equity Holdings, Inc., (CRWE) affiliates, officers, directors, contractors and employees, including may buy and sell additional shares in any company mentioned herein and may profit in the event those shares rise in value. Please do your own Due Diligence before investing in any of the stocks mentioned above.
About Power3 Medical Products, Inc
Power3 Medical Products (OTC BB:PWRM.OB) (www.power3medical.com)
Power3 expects to complete phase II clinical validation trials of its blood serum diagnostics for Alzheimer's and Parkinson's disease (NuroPro AD and PD), in the fourth quarter of 2009, followed by completion of filing with the FDA. Power3 operates a state-of-the-
Never invest in any stock featured on our sites, emails or alerts unless you can afford to lose your entire investment.
*********************************************************
The disclaimer is to be read and fully understood before using our sites, stock alerts or joining our email list.
CRWENewswire.com, and Crown Equity Holdings, Inc. associates, consultants, employees are not registered as Investment Advisor or Broker Dealer in any jurisdiction whatsoever. Full disclaimer can be read at http://www.crwenewswire.com.
Release of Liability: Through use of our website, Email Alerts, and stock alerts viewing or using, you agree to hold Crown Equity Holdings, Inc., its operators, shareholders, consultants, associates and employees harmless and to completely release them from any and all liability due to any and all loss (monetary or otherwise), damage (monetary or otherwise), or injury (monetary or otherwise) that you may incur. The information contained herein is based on sources which we believe to be reliable but is not guaranteed by us as being accurate and does not purport to be a complete statement or summary of the available data. CRWENewswire.com and Crown Equity Holdings, Inc. affiliates and associates may from time to time have a position in the securities mentioned herein and may increase or decrease such positions without notice. Crown Equity Holdings, Inc. encourages readers and investors to supplement the information in these reports with independent research and other professional advice. All information on featured companies is provided by the companies profiled, or is available from public sources and CRWENewswire.com makes no representations, warranties or guarantees as to the accuracy or completeness of the disclosure by the profiled companies.
Forward-Looking Statement: This release may contain forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. All forward-looking statements and/or Safe Harbor Statement under the Private Securities Litigation Reform Act of 1995 are inherently uncertain as they are based on current expectations and assumptions concerning future events or future performance of the company. Readers are cautioned not to place undue reliance on these forward-looking statements, which are only predictions and speak only as of the date hereof. Risks and uncertainties applicable to the company and its business could cause the company's actual results to differ materially from those indicated in any forward-looking statements.
Source: Power3 Medical Products, Inc.
